Abstract Disease Overview: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …

Introduction: Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-
cell lymphomas. Zanubrutinib was designed to achieve improved therapeutic concentrations …

Digital twins employ mathematical and computational models to virtually represent a
physical object (eg, planes and human organs), predict the behavior of the object, and …

In the last few decades, there has been a growing interest in Bruton's tyrosine kinase (BTK)
and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) …

Bruton's tyrosine kinase (BTK), a member of the Tec kinase family, is critically involved in a
range of immunological pathways. The clinical application of BTK inhibitors for B‐cell …

The phase III ASPEN study demonstrated the comparable efficacy and improved safety of
zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here …

Starting with the first-in-class agent ibrutinib, the development of Bruton tyrosine kinase
(BTK) inhibitors has led to dramatic improvements in the management of B-cell …

Scope The objective of this guideline is to provide healthcare professionals with clear
guidance on the management of patients with Waldenström macroglobulinaemia. In …

The B-cell receptor signalling pathway plays a critical role in development of B-cell
malignancies, and the central role of Bruton's tyrosine kinase (BTK) activation in this …

Bruton's tyrosine kinase inhibitors (BTKis) have altered the treatment landscape for chronic
lymphocytic leukemia (CLL) by offering effective and well-tolerated therapeutic options …